Published 3 days ago • loading... • Updated 2 days ago

Ollin Biosciences Reports Positive Head-to-Head Phase 1b Results for OLN324 in DME and Wet AMD

On Jan. 8, 2026, Innovent Biologics announced Ollin Biosciences reported positive topline Phase 1b JADE results comparing IBI324 with faricimab in DME and wAMD from San Francisco and Suzhou, China.
IBI324, a next-generation VEGF/Ang2 bispecific, was compared to faricimab in the JADE Phase 1b study to assess clinical performance.
OLN324's smaller protein format and higher molar dose differentiate its profile, with company materials saying it shows up to 60-fold higher anti-Ang2 potency.
Ollin released topline results from the randomized, head-to-head JADE Phase 1b study, disclosed by Innovent Biologics, Inc. .
Early-Phase topline evidence positions IBI324 in direct clinical comparison to faricimab, with Phase 1b topline evidence providing early data and company materials citing OLN324's differentiated first-line standard-of-care profile.

Insights by Ground AI

18 Articles

Montana Standard

+17 Reposted by 17 other sources

Center

Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration

SAN FRANCISCO and SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major…

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year